Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Lexin (LX.US) Releases Q4 Financial Report: Diversified Ecosystem Business Shows Resilience, Company Operations Remain Stable, Rapid Growth in Active Quality Users

Lexin (LX.US) Releases Q4 Financial Report: Diversified Ecosystem Business Shows Resilience, Company Operations Remain Stable, Rapid Growth in Active Quality Users

老虎证券老虎证券2026/03/19 14:30
Show original
Facing ongoing challenges brought by the macroeconomic environment and industry cycle adjustments, Lexin's diversified business ecosystem further demonstrated resilience in the fourth quarter, and the company's overall operations remained stable. Driven by the philosophy of long-termism, the company's ability to withstand cyclical fluctuations has been further enhanced. In the fourth quarter, the company achieved revenue of 3 billions yuan; profit (Non-GAAP EBIT) was 299 millions yuan. For the full year of 2025, the company's profit (Non-GAAP EBIT) is expected to reach 2.216 billions yuan.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

From $617 to $350: CVS Sets "Break-Even Price" for Weight-Loss Drugs, Says Pharmaceutical Companies Can Still Profit

An analysis of insurance claims data found that if GLP-1 drugs used for weight loss and diabetes are priced below $350 per month, payers—such as employers and plan sponsors—would achieve net savings due to a decrease in related healthcare service utilization.

智通财经•2026/11/15 04:01
From $617 to $350: CVS Sets "Break-Even Price" for Weight-Loss Drugs, Says Pharmaceutical Companies Can Still Profit